CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 5 enrolled
Drug / intervention
99mTc-Macro Albumin Aggregatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05848947
NCT05848947Phase 4Completed
CompareCT.gov

Study to Calculate the Radiation-Absorbed Dose of Technetium-99m Macroaggregated Albumin (99mTc-MAA) to the Whole Body and Non-Liver Critical Organs

Sirtex Medical·interventional·Posted May 8, 2023·Updated Jan 29, 2025

In Brief

A Phase 4 clinical trial evaluating 99mTc-Macro Albumin Aggregate for Carcinoma and 2 related conditions. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
CountriesUnited States
CollaboratorsBright Research Partners

Timeline

Phase 4CompletedFinished
202420252026
First PostedMay 8, 2023
Enrollment StartApr 25, 2023
Primary CompletionJul 5, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.1 years ago

Interventions

99mTc-Macro Albumin Aggregatedrug

Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.